Efficacy and safety of neuronox
Botulinum toxin type A
efficacy
lateral canthal lines
neuronox
onabotulinumtoxin a
safety
Journal
The Journal of dermatological treatment
ISSN: 1471-1753
Titre abrégé: J Dermatolog Treat
Pays: England
ID NLM: 8918133
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
pubmed:
2
11
2019
medline:
13
7
2021
entrez:
1
11
2019
Statut:
ppublish
Résumé
Neuronox This study was a randomized, double-blind, active drug controlled, multicenter, 16 week, Phase I/III study designed to determine the non-inferiority of Neuronox The primary endpoint was achieved as the proportion of responders was 83% for both Neuronox Treatment of moderate to severe LCL with Neuronox
Identifiants
pubmed: 31665942
doi: 10.1080/09546634.2019.1687818
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
onabotulinum toxin A
EC 3.4.24.69
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM